The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 21, 2023
Filed:
Mar. 27, 2019
Applicant:
Dana-farber Cancer Institute, Inc., Boston, MA (US);
Inventors:
F. Stephen Hodi, Framingham, MA (US);
Jun Zhou, Waltham, MA (US);
Gordon J. Freeman, Brookline, MA (US);
Jingjing Li, Lexington, MA (US);
Xinqi Wu, Chestnut Hill, MA (US);
Assignee:
Dana-Farber Cancer Institute, Inc., Boston, MA (US);
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/00 (2006.01); C07K 14/705 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); G01N 33/50 (2006.01); G01N 33/574 (2006.01); A61K 9/00 (2006.01); A61K 38/17 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); C12Q 1/6886 (2018.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 14/70532 (2013.01); A61K 9/0019 (2013.01); A61K 38/1774 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); C07K 14/70596 (2013.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); C07K 16/3053 (2013.01); C12Q 1/6886 (2013.01); G01N 33/5011 (2013.01); G01N 33/5743 (2013.01); A61K 38/00 (2013.01); A61K 2039/505 (2013.01); C07K 2319/30 (2013.01); C12Q 2600/118 (2013.01); C12Q 2600/136 (2013.01); C12Q 2600/158 (2013.01); G01N 2333/70596 (2013.01); G01N 2500/10 (2013.01); G01N 2800/52 (2013.01);
Abstract
The present invention relates to compositions and methods for identifying, assessing, preventing, and treating melanoma. A variety of PD-L1 isoform biomarkers are provided, wherein alterations in the copy number of one or more of the biomarkers and/or alterations in the amount, structure, and/or activity of one or more of the biomarkers is associated with melanoma status.